CHRNA7 and early-onset autosomal dominant Alzheimer disease: This is in accord with previously reported data on the positive effects of α7 nAChR agonists in Alzheimer’s disease animal models (Van Kampen et al., 2004; Boess et al., 2007; Medeiros et al., 2014; Vicens et al., 2017; reviewed in Foucault-Fruchard and Antier, 2017).